These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 34485029)

  • 21. SARS, MERS and SARS-CoV-2 (COVID-19) treatment: a patent review.
    Nascimento Junior JAC; Santos AM; Quintans-Júnior LJ; Walker CIB; Borges LP; Serafini MR
    Expert Opin Ther Pat; 2020 Aug; 30(8):567-579. PubMed ID: 32429703
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Molecular Insights of SARS-CoV-2 Infection and Molecular Treatments.
    Abdurrahman L; Fang X; Zhang Y
    Curr Mol Med; 2022; 22(7):621-639. PubMed ID: 34645374
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Discovery of a "Cocktail" of Potential SARS-COV-2 Main Protease Inhibitors through Virtual Screening of Known Chemical Components of Vitex negundo L. ("Lagundi").
    Cayona R; Creencia E
    Med Chem; 2022; 18(3):364-381. PubMed ID: 34148541
    [TBL] [Abstract][Full Text] [Related]  

  • 24. TMPRSS2 and RNA-Dependent RNA Polymerase Are Effective Targets of Therapeutic Intervention for Treatment of COVID-19 Caused by SARS-CoV-2 Variants (B.1.1.7 and B.1.351).
    Lee J; Lee J; Kim HJ; Ko M; Jee Y; Kim S
    Microbiol Spectr; 2021 Sep; 9(1):e0047221. PubMed ID: 34378968
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Approaches and advances in the development of potential therapeutic targets and antiviral agents for the management of SARS-CoV-2 infection.
    Krishna G; Pillai VS; Veettil MV
    Eur J Pharmacol; 2020 Oct; 885():173450. PubMed ID: 32739174
    [TBL] [Abstract][Full Text] [Related]  

  • 26. An efficient chemical screening method for structure-based inhibitors to nucleic acid enzymes targeting the DNA repair-replication interface and SARS CoV-2.
    Moiani D; Link TM; Brosey CA; Katsonis P; Lichtarge O; Kim Y; Joachimiak A; Ma Z; Kim IK; Ahmed Z; Jones DE; Tsutakawa SE; Tainer JA
    Methods Enzymol; 2021; 661():407-431. PubMed ID: 34776222
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Repurposing Screens of FDA-Approved Drugs Identify 29 Inhibitors of SARS-CoV-2.
    Ku KB; Shin HJ; Kim HS; Kim BT; Kim SJ; Kim C
    J Microbiol Biotechnol; 2020 Dec; 30(12):1843-1853. PubMed ID: 33203821
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Potential of
    Foka FET; Manamela N; Mufamadi SM; Mufhandu HT
    Biomed Res Int; 2022; 2022():5714035. PubMed ID: 36158879
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A Mechanistic Review on Plant-derived Natural Inhibitors of Human Coronaviruses with Emphasis on SARS-COV-1 and SARS-COV-2.
    Guguloth SK; Lakshmi AR; Rajendran R; Rajaram K; Chinnasamy T; Huang JD; Zhang H; Senapati S; Durairajan SSK
    Curr Drug Targets; 2022; 23(8):818-835. PubMed ID: 34636297
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Current approaches for target-specific drug discovery using natural compounds against SARS-CoV-2 infection.
    Khare P; Sahu U; Pandey SC; Samant M
    Virus Res; 2020 Dec; 290():198169. PubMed ID: 32979476
    [TBL] [Abstract][Full Text] [Related]  

  • 31. GC-MS profiling of Bauhinia variegata major phytoconstituents with computational identification of potential lead inhibitors of SARS-CoV-2 M
    More-Adate P; Lokhande KB; Swamy KV; Nagar S; Baheti A
    Comput Biol Med; 2022 Aug; 147():105679. PubMed ID: 35667152
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Advances in the development of therapeutic strategies against COVID-19 and perspectives in the drug design for emerging SARS-CoV-2 variants.
    Yin J; Li C; Ye C; Ruan Z; Liang Y; Li Y; Wu J; Luo Z
    Comput Struct Biotechnol J; 2022; 20():824-837. PubMed ID: 35126885
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Exploring the dual effect of novel 1,4-diarylpyranopyrazoles as antiviral and anti-inflammatory for the management of SARS-CoV-2 and associated inflammatory symptoms.
    Malebari AM; E A Ahmed H; Ihmaid SK; Omar AM; Muhammad YA; Althagfan SS; Aljuhani N; A A El-Sayed AA; Halawa AH; El-Tahir HM; Turkistani SA; Almaghrabi M; K B Aljohani A; El-Agrody AM; Abulkhair HS
    Bioorg Chem; 2023 Jan; 130():106255. PubMed ID: 36403336
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Broad-spectrum antiviral activity of Spatholobus suberectus Dunn against SARS-CoV-2, SARS-CoV-1, H5N1, and other enveloped viruses.
    Liu Q; Kwan KY; Cao T; Yan B; Ganesan K; Jia L; Zhang F; Lim C; Wu Y; Feng Y; Chen Z; Liu L; Chen J
    Phytother Res; 2022 Aug; 36(8):3232-3247. PubMed ID: 35943221
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Current Strategies in Treating Cytokine Release Syndrome Triggered by Coronavirus SARS-CoV-2.
    Wang LG; Wang L
    Immunotargets Ther; 2022; 11():23-35. PubMed ID: 35611161
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Neutralization of SARS-CoV-2 Spike Protein via Natural Compounds: A Multilayered High Throughput Virtual Screening Approach.
    Dhasmana A; Kashyap VK; Dhasmana S; Kotnala S; Haque S; Ashraf GM; Jaggi M; Yallapu MM; Chauhan SC
    Curr Pharm Des; 2020; 26(41):5300-5309. PubMed ID: 32867645
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Discovery of S-217622, a Noncovalent Oral SARS-CoV-2 3CL Protease Inhibitor Clinical Candidate for Treating COVID-19.
    Unoh Y; Uehara S; Nakahara K; Nobori H; Yamatsu Y; Yamamoto S; Maruyama Y; Taoda Y; Kasamatsu K; Suto T; Kouki K; Nakahashi A; Kawashima S; Sanaki T; Toba S; Uemura K; Mizutare T; Ando S; Sasaki M; Orba Y; Sawa H; Sato A; Sato T; Kato T; Tachibana Y
    J Med Chem; 2022 May; 65(9):6499-6512. PubMed ID: 35352927
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A robust high-throughput fluorescence polarization assay for rapid screening of SARS-CoV-2 papain-like protease inhibitors.
    Yan H; Liu Z; Yan G; Liu X; Liu X; Wang Y; Chen Y
    Virology; 2022 Sep; 574():18-24. PubMed ID: 35870326
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cameroonian medicinal plants as potential candidates of SARS-CoV-2 inhibitors.
    Fouedjou RT; Chtita S; Bakhouch M; Belaidi S; Ouassaf M; Djoumbissie LA; Tapondjou LA; Abul Qais F
    J Biomol Struct Dyn; 2022; 40(19):8615-8629. PubMed ID: 33908318
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The FDA-Approved Drug Cobicistat Synergizes with Remdesivir To Inhibit SARS-CoV-2 Replication
    Shytaj IL; Fares M; Gallucci L; Lucic B; Tolba MM; Zimmermann L; Adler JM; Xing N; Bushe J; Gruber AD; Ambiel I; Taha Ayoub A; Cortese M; Neufeldt CJ; Stolp B; Sobhy MH; Fathy M; Zhao M; Laketa V; Diaz RS; Sutton RE; Chlanda P; Boulant S; Bartenschlager R; Stanifer ML; Fackler OT; Trimpert J; Savarino A; Lusic M
    mBio; 2022 Apr; 13(2):e0370521. PubMed ID: 35229634
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.